RT Journal Article
SR Electronic
T1 Ethnic differences in acetylcholinesterase inhibitor use for Alzheimer disease
JF Neurology
JO Neurology
FD Lippincott Williams & Wilkins
SP 159
OP 162
DO 10.1212/01.wnl.0000167545.38161.48
VO 65
IS 1
A1 Kala M. Mehta
A1 Maggie Yin
A1 Cynthia Resendez
A1 Kristine Yaffe
YR 2005
UL http://n.neurology.org/content/65/1/159.abstract
AB Acetylcholinesterase inhibitors (AChIs) have been demonstrated to improve Alzheimer disease symptoms. Whether the use of AChIs varies by ethnicity is unknown. More than 2500 ethnically diverse patients (6% African American, 14% Latino, and 7% Asian patients) from the Alzheimer’s Disease Research Centers in California were studied. Compared with white patients with AD, minority patients had 40% lower odds of AChI use (odds ratio 0.6, 95% confidence interval: 0.5 to 0.7).